// App-Quantinova.ai

FRI0108 : ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES

Researchers

Presenter

  • J. Tesser

Principal Investigators

  • G. C. Wright

  • V. Strand

  • J. Kaine

  • K. Maslova

  • G. St John

  • K. Ford

  • A. Praestgaard

  • E. Choy

Medical Centers

  • Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, United States of America

  • NYU Langone Medical Center, New York, NY, United States of America

  • VA Palo Alto HCS/ Stanford University, Palo Alto, California, United States

  • Sarasota Arthritis Research Center, Sarasota, United States

  • Sanofi Genzyme, Cambridge, MA, United States

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • Cardiff University, Cardiff, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Adalimumab

  • Sarilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01061736

  • NCT01709578

  • NCT02332590

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved